LONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Gemmis is indicated for the treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer and biliary tract cancer. Gemmis is indicated in combination with paclitaxel for anthracycline-treated failure locally-recurred inoperable breast cancer or metastatic breast cancer after failure of prior anthracycline-containing adjuvant or metastatic chemotherapy. Gemmis is indicated in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy.
Irino is indicated for the treatment of patients with advanced colorectal cancer:
1. In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
2. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
Breast cancer, non-small cell lung cancer, prostate cancer, head and neck cancer, gastric adenocarcinoma.
Painkyl is an opioid analgesic indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking at least: 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.
Granisetron extended-release subQ injection is indicated for the prevention of acute and delayed chemotherapy-associated nausea and vomiting in patients receiving regimens with an anthracycline in combination with cyclophosphamide.
It may be used for initial and repeat chemotherapy courses, and must be used in combination with other antiemetics (eg, dexamethasone, neurokinase-1 receptor antagonists).
Bone metastases from solid tumors: Treatment of documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy); prostate cancer should have progressed following treatment with at least one hormonal therapy.
Hypercalcemia of malignancy: Treatment of hypercalcemia (albumin-corrected serum calcium ≥12 mg/dL) of malignancy. Multiple myeloma: Treatment of osteolytic lesions of multiple myeloma.